BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 21663508)

  • 1. Efficacy and safety of rituximab treatment in patients with progressive transformation of germinal centers after Hodgkin lymphoma in complete remission post-induction chemotherapy and radiotherapy.
    Picardi M; Zeppa P; Ciancia G; Pettinato G; Grimaldi F; Fabbricini R; Mainolfi C; Pane F
    Leuk Lymphoma; 2011 Nov; 52(11):2082-9. PubMed ID: 21663508
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Progressive transformation of germinal centers and Hodgkin lymphoma: more insights but maybe more confusion?
    Sweetenham JW; Polliack A
    Leuk Lymphoma; 2011 Nov; 52(11):2041-2. PubMed ID: 21888616
    [No Abstract]   [Full Text] [Related]  

  • 3. Treatment of relapsed CD20+ Hodgkin lymphoma with the monoclonal antibody rituximab is effective and well tolerated: results of a phase 2 trial of the German Hodgkin Lymphoma Study Group.
    Rehwald U; Schulz H; Reiser M; Sieber M; Staak JO; Morschhauser F; Driessen C; Rudiger T; Muller-Hermelink K; Diehl V; Engert A;
    Blood; 2003 Jan; 101(2):420-4. PubMed ID: 12509381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Complete remission of relapsed mixed cellularity Hodgkin's disease treated with rituximab].
    Al-Ali HK; Wittekind C; Niederwieser D
    Dtsch Med Wochenschr; 2007 Aug; 132(33):1688-91. PubMed ID: 17713864
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A multicentre, phase II trial of ofatumumab monotherapy in relapsed/progressive diffuse large B-cell lymphoma.
    Coiffier B; Radford J; Bosly A; Martinelli G; Verhoef G; Barca G; Davies A; Decaudin D; Gallop-Evans E; Padmanabhan-Iyer S; Van Eygen K; Wu KL; Gupta IV; Lin TS; Goldstein N; Jewell RC; Winter P; Lisby S;
    Br J Haematol; 2013 Nov; 163(3):334-42. PubMed ID: 24032456
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of rituximab in newly diagnosed stage IA nodular lymphocyte-predominant Hodgkin lymphoma: a report from the German Hodgkin Study Group.
    Eichenauer DA; Fuchs M; Pluetschow A; Klimm B; Halbsguth T; Böll B; von Tresckow B; Nogová L; Borchmann P; Engert A
    Blood; 2011 Oct; 118(16):4363-5. PubMed ID: 21828141
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rituximab in lymphocyte-predominant Hodgkin disease: results of a phase 2 trial.
    Ekstrand BC; Lucas JB; Horwitz SM; Fan Z; Breslin S; Hoppe RT; Natkunam Y; Bartlett NL; Horning SJ
    Blood; 2003 Jun; 101(11):4285-9. PubMed ID: 12586628
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mature results of a phase II study of rituximab therapy for nodular lymphocyte-predominant Hodgkin lymphoma.
    Advani RH; Horning SJ; Hoppe RT; Daadi S; Allen J; Natkunam Y; Bartlett NL
    J Clin Oncol; 2014 Mar; 32(9):912-8. PubMed ID: 24516013
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoarchitectural patterns of progressive transformation of germinal centers with and without nodular lymphocyte-predominant Hodgkin lymphoma.
    Hartmann S; Winkelmann R; Metcalf RA; Treetipsatit J; Warnke RA; Natkunam Y; Hansmann ML
    Hum Pathol; 2015 Nov; 46(11):1655-61. PubMed ID: 26410017
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database.
    Ban-Hoefen M; Vanderplas A; Crosby-Thompson AL; Abel GA; Czuczman MS; Gordon LI; Kaminski MS; Kelly J; Millenson M; Nademanee AP; Rodriguez MA; Zelenetz AD; Niland J; LaCasce AS; Friedberg JW
    Br J Haematol; 2013 Nov; 163(4):487-95. PubMed ID: 24111533
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of nodular lymphocyte predominant Hodgkin lymphoma in the modern era.
    King MT; Donaldson SS; Link MP; Natkunam Y; Advani RH; Hoppe RT
    Int J Radiat Oncol Biol Phys; 2015 May; 92(1):67-75. PubMed ID: 25863755
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rituximab anti-CD20 monoclonal antibody therapy in non-Hodgkin's lymphoma: safety and efficacy of re-treatment.
    Davis TA; Grillo-López AJ; White CA; McLaughlin P; Czuczman MS; Link BK; Maloney DG; Weaver RL; Rosenberg J; Levy R
    J Clin Oncol; 2000 Sep; 18(17):3135-43. PubMed ID: 10963642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
    Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
    Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intralesional administration of rituximab for treatment of CD20 positive orbital lymphoma: safety and efficacy evaluation.
    Laurenti L; De Padua L; Battendieri R; Tarnani M; Sica S; Blasi MA; Savino G; Leone G
    Leuk Res; 2011 May; 35(5):682-4. PubMed ID: 21334067
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Yttrium 90-ibritumomab tiuxetan plus rituximab maintenance as initial therapy for patients with high-tumor-burden follicular lymphoma: a Wisconsin Oncology Network study.
    Rajguru S; Kristinsdottir T; Eickhoff J; Peterson C; Meyer CM; Traynor AM; Kahl BS
    Clin Adv Hematol Oncol; 2014 Aug; 12(8):509-15. PubMed ID: 25356575
    [TBL] [Abstract][Full Text] [Related]  

  • 16. How I treat nodular lymphocyte predominant Hodgkin lymphoma.
    Advani RH; Hoppe RT
    Blood; 2013 Dec; 122(26):4182-8. PubMed ID: 24215035
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab monotherapy with eight weekly infusions for relapsed or refractory patients with indolent B cell non-Hodgkin lymphoma mostly pretreated with rituximab: a multicenter phase II study.
    Tobinai K; Igarashi T; Itoh K; Kurosawa M; Nagai H; Hiraoka A; Kinoshita T; Uike N; Ogura M; Nawano S; Mori S; Ohashi Y;
    Cancer Sci; 2011 Sep; 102(9):1698-705. PubMed ID: 21645173
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-CD20 monoclonal antibody (rituximab) for therapy of CD20-positive nodular lymphocyte-predominant Hodgkin lymphoma in an 10-year-old girl.
    Culić S; Armanda V; Kuljis D; Kuzmic I; Pranic-Kragic A; Jankovic S
    Pediatr Hematol Oncol; 2006 Dec; 23(8):661-6. PubMed ID: 17065142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Randomized Phase II Trial Comparing Obinutuzumab (GA101) With Rituximab in Patients With Relapsed CD20+ Indolent B-Cell Non-Hodgkin Lymphoma: Final Analysis of the GAUSS Study.
    Sehn LH; Goy A; Offner FC; Martinelli G; Caballero MD; Gadeberg O; Baetz T; Zelenetz AD; Gaidano G; Fayad LE; Buckstein R; Friedberg JW; Crump M; Jaksic B; Zinzani PL; Padmanabhan Iyer S; Sahin D; Chai A; Fingerle-Rowson G; Press OW
    J Clin Oncol; 2015 Oct; 33(30):3467-74. PubMed ID: 26282650
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential application of chemotherapy and monoclonal CD 20 antibody: successful treatment of advanced composite-lymphoma.
    Linck D; Lentini G; Tiemann M; Fauser AA; Parwaresch R; Basara N
    Leuk Lymphoma; 2005 Feb; 46(2):285-8. PubMed ID: 15621815
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.